Schizophrenia Mental and Behavioural Disorders
Conditions
Interventions
This was designed for a double-blinded, placebo-controlled, randomized clinical trial (RCT) of oral arachidonic acid (AA) supplementation to identify whether the adjunctive intervention can improve co
Sponsors
National Natural Science Foundation of China
Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients of SZ were diagnosed according to the International Classification of Diseases 10th edition (ICD-10) 2. The patient's family members or legal guardians fully understood the content of this study and signed informed consent
Exclusion criteria
Exclusion criteria: 1. Patients should not have a history of other mental disorders, neurological disorders, serious physical diseases, traumatic brain injury, substance abuse, or dependence 2. Healthy controls should not have any current or previous psychiatric history or family history, as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function was measured using the Cambridge Neuropsychological Test Automated Battery® (CANTAB®) system at baseline, week 3, and 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. RBC's lipids and fatty acids were measured using gas chromatography-mass spectrometry at baseline and week 6 2. Mitochondria lipids measured using ultrahigh-performance liquid chromatography quadrupole orbitrap mass spectrometry at baseline and endpoint 3. RNA sequencing of white blood cells was conducted at baseline and endpoint 4. Niacin skin flushing response test using 6 concentrations (triple gradient dilution from 60 mM) of niacin dropped onto the skin at baseline, week 3, and 6 | — |
Countries
China
Contacts
Public ContactXiaowen;Yan Hu;Gao
;
Outcome results
None listed